Literature DB >> 9180357

Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens.

I Melero1, N Bach, L Chen.   

Abstract

Despite the fact that many tumors express MHC class I molecules presenting "foreign" peptide antigens, a vigorous tumor-destructing immune response is seldom detected. A possible explanation is that tumors cannot provide adequate costimulatory signals as provided by professional antigen presenting cells. CD28, upon interacting with B7, triggers costimulatory signals critical for the T-cell response. Transfection of tumor cells with B7 augments the immunogenicity of the tumor so that an anti-tumor immune response can be amplified. When B7-CD28 costimulation is provided CTL specific for otherwise silent epitopes can be activated. Therefore, unresponsiveness of T cells to many tumor antigens should be considered as ignorance rather than tolerance. Immunological ignorance may thus contribute to the failure of the immune system to respond against the tumor antigens.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9180357     DOI: 10.1016/s0024-3205(96)00686-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  11 in total

Review 1.  The many sounds of T lymphocyte silence.

Authors:  Ignacio Melero; Ainhoa Arina; Lieping Chen
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 2.  Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience.

Authors:  Pierpaolo Correale; Maria Grazia Cusi; Lucia Micheli; Cristina Nencini; Maria Teresa Del Vecchio; Francesco Torino; Angelo Aquino; Enzo Bonmassar; Guido Francini; Giorgio Giorgi
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

3.  Expression of B7 costimulation molecules by colorectal cancer cells reducestumorigenicity and induces anti-tumor immunity.

Authors:  Jin-Yue Hu; Sa Wang; Jian-Gao Zhu; Guo-Hua Zhou; Qu-Bing Sun
Journal:  World J Gastroenterol       Date:  1999-04       Impact factor: 5.742

Review 4.  Enhancing efficacy of therapeutic vaccinations by combination with other modalities.

Authors:  James L Gulley; Ravi A Madan; Philip M Arlen
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

5.  Combining Vaccines with Conventional Therapies for Cancer.

Authors:  Philip M Arlen; Ravi A Madan; James W Hodge; Jeffrey Schlom; James L Gulley
Journal:  Update Cancer Ther       Date:  2007-03

6.  Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma.

Authors:  K Hiraoka; M Miyamoto; Y Cho; M Suzuoki; T Oshikiri; Y Nakakubo; T Itoh; T Ohbuchi; S Kondo; H Katoh
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

7.  A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.

Authors:  P Correale; L Micheli; M T Vecchio; M Sabatino; R Petrioli; D Pozzessere; S Marsili; G Giorgi; L Lozzi; P Neri; G Francini
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

Review 8.  How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development.

Authors:  Guillaume Darrasse-Jèze; Katrina Podsypanina
Journal:  Front Immunol       Date:  2013-09-26       Impact factor: 7.561

Review 9.  CD8+ T cell differentiation and dysfunction in cancer.

Authors:  Mary Philip; Andrea Schietinger
Journal:  Nat Rev Immunol       Date:  2021-07-12       Impact factor: 108.555

Review 10.  Initial afferent lymphatic vessels controlling outbound leukocyte traffic from skin to lymph nodes.

Authors:  Alvaro Teijeira; Ana Rouzaut; Ignacio Melero
Journal:  Front Immunol       Date:  2013-12-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.